Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelGlobeNewsWire • 05/28/24
Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 05/20/24
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialGlobeNewsWire • 05/15/24
Atossa Therapeutics maintains strong cash position while advancing breast cancer therapy in Q1Proactive Investors • 05/13/24
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/13/24
Atossa Therapeutics welcomes updated breast cancer screening guidelinesProactive Investors • 05/07/24
Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesGlobeNewsWire • 05/07/24
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenGlobeNewsWire • 04/29/24
Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drugProactive Investors • 04/15/24
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewsWire • 04/15/24
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceGlobeNewsWire • 04/11/24
Atossa Therapeutics reports positive data from breast cancer treatment trialProactive Investors • 04/09/24
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenGlobeNewsWire • 04/09/24
Atossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestonesProactive Investors • 04/01/24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 04/01/24
Atossa Therapeutics' breast cancer drug milestone sparks investor enthusiasmProactive Investors • 03/20/24
Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifenProactive Investors • 03/19/24
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientGlobeNewsWire • 03/19/24
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsGlobeNewsWire • 03/18/24